Patricia Inácio, PhD,  science writer—

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Depression, Anxiety Common Among CF Patients

Depression and anxiety are common among people with cystic fibrosis (CF), a systematic review reports. The study “Global Burden of Anxiety and Depression among Cystic Fibrosis Patient: Systematic Review and Meta-Analysis” was published in the International Journal of Chronic Diseases. In people with CF, a genetic defect…

Online Art, Music and Exercise Programs Win CFF Impact Grants

This year’s Cystic Fibrosis Foundation (CFF) Impact Grants will support three new virtual programs that support the well-being of people of all ages living with cystic fibrosis (CF). These winning projects range from a virtual video performance with tailored songs for hospitalized children with CF, to online exercise classes for teenagers,…

Joint Disease More Common With P. aeruginosa Infection, Female Sex

Chronic Pseudomonas aeruginosa infection in adults with cystic fibrosis increases their likelihood of developing CF arthropathy, a painful inflammation of the joints, a German study reported. Additional risk factors for CF arthropathy include older age, female sex, and more severe disease. These findings were published in the Journal of Cystic Fibrosis, in…

Smartphone App Study to Assess How Trikafta Affects Daily Life

A first-of-its-kind, observational study will allow patients with cystic fibrosis (CF) to use their smartphones to monitor the ways in which Trikafta (elexacaftor/tezacaftor/ivacaftor) affects their daily lives. Sponsored by the Cystic Fibrosis Foundation, the now-enrolling HERO-2 study (NCT04798014) will collect patients’ self-reported feedback for one year…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.